Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 4
2008 4
2009 4
2010 4
2011 3
2012 2
2013 2
2014 1
2015 1
2019 1
2022 1
2023 2
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Toorop AA, Wessels MH, Boonkamp L, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Strijbis EM, van Oosten BW, de Jong BA, Uitdehaag BM, Rispens T, Killestein J, van Kempen ZL, Teunissen CE. Toorop AA, et al. Among authors: kragt jj. Mult Scler. 2024 Nov;30(13):1683-1688. doi: 10.1177/13524585241293940. Epub 2024 Nov 4. Mult Scler. 2024. PMID: 39494701 Free PMC article.
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
Gelissen LMY, Toorop AA, Schipper PM, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert J, Wokke B, Kalkers NF, Hoogervorst ELJ, van Eijk J, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, Bouvy WH, Strijbis EM, Oosten BV, De Jong BA, Uitdehaag BMJ, Lissenberg-Witte BI, Loeff FC, Rispens T, Killestein J, van Kempen ZLE. Gelissen LMY, et al. Among authors: kragt jj. J Neurol Neurosurg Psychiatry. 2025 Oct 15;96(11):1038-1045. doi: 10.1136/jnnp-2024-335761. J Neurol Neurosurg Psychiatry. 2025. PMID: 40132877 Free article.
Gender differences in multiple sclerosis: cytokines and vitamin D.
Eikelenboom MJ, Killestein J, Kragt JJ, Uitdehaag BM, Polman CH. Eikelenboom MJ, et al. Among authors: kragt jj. J Neurol Sci. 2009 Nov 15;286(1-2):40-2. doi: 10.1016/j.jns.2009.06.025. Epub 2009 Aug 4. J Neurol Sci. 2009. PMID: 19656528 Review.
Clinician-patient communication during the diagnostic workup: The ABIDE project.
Visser LNC, Kunneman M, Murugesu L, van Maurik I, Zwan M, Bouwman FH, Schuur J, Wind HA, Blaauw MSJ, Kragt JJ, Roks G, Boelaarts L, Schipper AC, Schooneboom N, Scheltens P, van der Flier WM, Smets EMA. Visser LNC, et al. Among authors: kragt jj. Alzheimers Dement (Amst). 2019 Jul 29;11:520-528. doi: 10.1016/j.dadm.2019.06.001. eCollection 2019 Dec. Alzheimers Dement (Amst). 2019. PMID: 31388556 Free PMC article.
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Toorop AA, Wessels MHJ, Gelissen LMY, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert JP, Wokke BHA, Kalkers NF, Hoogervorst ELJ, van Eijk JJJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, van Dijk GW, Bouvy WH, Strijbis EMM, van Oosten BW, de Jong BA, Lissenberg-Witte BI, Rispens T, Uitdehaag BMJ, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: kragt jj. J Neurol Sci. 2024 Jul 15;462:123102. doi: 10.1016/j.jns.2024.123102. Epub 2024 Jun 22. J Neurol Sci. 2024. PMID: 38925067 Free article. Clinical Trial.
The size of the treatment effect: do patients and proxies agree?
van der Linden FA, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BM. van der Linden FA, et al. Among authors: kragt jj. BMC Neurol. 2009 Mar 25;9:12. doi: 10.1186/1471-2377-9-12. BMC Neurol. 2009. PMID: 19317921 Free PMC article.
30 results